Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphomannomutase 2 is a cytoplasmic enzyme, encoded by the PMM2 gene, that catalyzes the interconversion of mannose-6-phosphate to mannose-1-phosphate, a key step in the glycosylation pathway which is critical for the proper attachment of sugar chains (N-glycans) to proteins. This process is essential for the formation of dolichol-P-oligosaccharides used in N-linked protein glycosylation. Mutations in the PMM2 gene result in reduced enzyme activity and can cause congenital disorder of glycosylation type Ia (PMM2-CDG), which features developmental disabilities, hypotonia, fat distribution abnormalities, and other multi-organ symptoms. PMM2 is a member of the haloalkanoate dehalogenase superfamily and is essential for normal cellular and tissue development
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphomannomutase 2 (PMM2).